Abstract
ABSTRACT Objective: We describe the pressure lowering effect of micropulse laser trabeculoplasty (MLT) in patients with uncontrolled open angle glaucoma (OAG). Design: Retrospective case series. Methods: We retrospective reviewed 30 eyes with Open angle Glaucoma (OAG) at the Vista Clinic in Lima, Peru. A single session of MLT treatment was delivered using a 532 nm Frequency doubled Nd. YAG laser to 360o of the trabecular meshwork with a power of 1000 mW, 25 % of duty cycle, and 300 ms. of exposure. The intraocular pressure (IOP) was measured at baseline and at 1 day, 1 week, 3, 6 months post-treatment and were followed up for one last control. Results: The mean baseline IOP was 15.6 mmHg and in the last control was12.8 mmHg, mean follow up time of 19 months (+/- 10 SD). The mean reduction of IOP in the first day was 1.6 mmHg (± 2.6 SD) and 1.2 mmHg (± 3.3 SD) in the last follow up. The mean percentage of IOP reduction was 17.9% and 7 eyes (40%) had IOP reduction greater than 20%. No statistical difference in relation to demographics characteristics of the patients. The greatest reduction was achieved in the first day with a median of 2.00 (P 0.001). A tendency to achieve higher reduction of IOP in patients with higher baseline IOP was found, but was not statistical significant. No adverse reactions occurred. Conclusions: Micropulse laser trabeculoplasty can temporarily be effective in reducing the IOP in some patients with uncontrolled Open angle glaucoma and appears to be safe.
Highlights
Glaucoma is the second leading cause of blindness worldwide and the leading cause of irreversible blindness, accounting for 8 % of all blindness, affecting an estimated 3.12 million blind people in the world.[1]
The use of laser in the trabeculum was initially described by Wise and Witter in 1979 with the Argon Laser trabeculoplasty (ALT),(6) and in 1995 Latina and Park begin to use the Selective Laser trabeculoplasty (SLT).(7,8) Since they become widely use for the treatment of Open angle glaucoma (OAG), and demonstrated to have similar efficacy to lower the intra ocular pressure (IOP) in comparison to topical medications avoiding their side effects.[9]. Other Several studies demonstrated the same efficacy between these two procedures, SLT has the advantage that it does not leave a noticeable scar on the trabeculum and is repeatable .(10-16)
We report on the pressure lowering effect of micropulse laser trabeculoplasty (MLT) in patients with uncontrolled open angle glaucoma of Peruvian eyes in Lima, Peru
Summary
Glaucoma is the second leading cause of blindness worldwide and the leading cause of irreversible blindness, accounting for 8 % of all blindness, affecting an estimated 3.12 million blind people in the world.[1]. Women will comprise 55% of OAG, 70% of angle closure glaucoma (ACG), and 59% of all glaucoma in 2020. Topical antiglaucoma medications are used before surgery since this last one is related to some complications, despite his efficiency to lower the IOP. The use of laser in the trabeculum was initially described by Wise and Witter in 1979 with the Argon Laser trabeculoplasty (ALT),(6) and in 1995 Latina and Park begin to use the Selective Laser trabeculoplasty (SLT).(7,8) Since they become widely use for the treatment of OAG, and demonstrated to have similar efficacy to lower the IOP in comparison to topical medications avoiding their side effects.[9] Other Several studies demonstrated the same efficacy between these two procedures, SLT has the advantage that it does not leave a noticeable scar on the trabeculum and is repeatable .(10-16)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
